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This studyaimed todevelophydrophilicmatrixbasedcontrolled releasegastroretentivedrug
delivery system of ofloxacin and conducting its in vitro and in vivo evaluations. Effervescent
floating gastroretentive drug delivery system of ofloxacin was prepared utilizing Boxe
Behnken statistical design with 3 factors, 3 levels and 15 experimental trials. Formulation
optimization was done by setting targets on selected responses. In vivo studies were carried
out for the optimized formulation with 12 healthy human volunteers and obtained phar-
macokineticparameterswere comparedwith themarketedoncedaily formulation, “Zanocin
OD”. Optimized formulation showed satisfactory controlled in vitro drug release for more
than 12 h with excellent buoyancy properties (floating lag time <1 min, floating duration
>16 h). Optimized and marketed formulations were found to have similar in vitro release
profile ( f2 ¼ 79.22) and also were found to be bioequivalent. Serum ofloxacin concentration
was well maintained above its reported minimum inhibitory concentrations for most of the
pathogens for sufficiently longer duration. Cmax and AUC values of optimized formulation
were found to be significantly higher than ofmarketed product despite their bioequivalence.
Bettertherapeutic effect can be expected since ofloxacin exhibits concentration dependent
killing. Hence, gastroretention can be a promising approach to enhance bioavailability of
ofloxacin with narrow absorption window in upper GIT.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction however has been limited because the actual time for effectiveThe importance of controlled drug delivery systems that
release drug over an extended period of time has long been
recognized in the pharmaceutical field. Application of such
controlled release technology to oral drug delivery systemþ977 9841299482 (mobile
).
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Gastric retention devices are designed to prolong the gastric
residence time of oral controlled release dosage forms. They
thus result in increased contact time for drugs that act locally,
increasedabsorptionofdrugs thathaveabsorptionwindows in).
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for drugs less soluble in the intestinal fluid [1]. Several ap-
proaches have been developed to achieve extended gastric
residence time of the oral drug delivery systems such as bio-
adhesive system, swelling and expanding systems, floating
systems and delayed gastric emptying devices. Amongst these
methods, floating drug delivery system is preferred one that
offers a simple and practical approach to achieve Gastro-
retention [2]. Floating dosage forms have a bulk density lower
than that of gastric fluids and therefore remain buoyant on the
stomach contents to prolong the gastric retention time [3e7].
Ofloxacin is widely used fluoroquinolone and has been
reported as one among the five most frequently prescribed
antibiotics in Nepal [8]. It is a broad spectrum antibiotic
effective against wide range of Gram-negative and Gram-
positive microorganisms. Biological half life of this drug is
from5 to 6 h due towhich frequent administration is required.
To avoid the drawbacks of frequent administrations such as
plasma level fluctuations and patient non-compliance it is
desirable to have a controlled release dosage forms of oflox-
acin. It has been reported that bioavailability of ofloxacin is
strongly dependent on the local physiology of GIT. It is readily
soluble in the acidic environment of the stomach and thus is
preferentially absorbed from the upper part of GIT [9]. In the
alkaline environment of intestine, precipitation of the drug
occurs decreasing its absorption.
This study was conducted with an aim to develop floating
gastroretentive tablet formulation incorporating 400 mg
ofloxacin into hydrophilic polymeric matrix which would
release the drug in stomach and upper part of GIT in a
controlled manner. Since ofloxacin has site-specific absorp-
tion from these regions, gastroretention of the dosage form
will improve its oral bioavailability [10e12].Table 1 e Independent variables and their levels in
BoxeBehnken design.
Level (mg per tablet)
Low Middle High
X1 (amount of HPMC K100M) 1 (40) 0 (70) þ1 (100)
X2 (amount of crosspovidone) 1 (60) 0 (105) þ1 (150)
X3 (amount of NaHCO3) 1 (60) 0 (75) þ1 (90)2. Materials and methods
2.1. Materials
Ofloxacin (Batch no. A5/206), hydroxypropyl methyl cellulose
(HPMC) K100M (Batch no. HP121406 MC) and crosspovidone
(Batch no. YPVPP09319040) were obtained from Nepal Phar-
maceutical Laboratories Pvt. Ltd., Birgunj, Nepal as gift sam-
ples. Sodium bicarbonate (NaHCO3), citric acid, polyvinyl
pyrrolidone (PVP K-30), magnesium stearate, lactose and iso-
propyl alcohol were purchased from local suppliers. Marketed
product, “Zanocin OD”, (manufactured by Ranbaxy, India;
Batch no. 2033597), used as a reference, was purchased from
the local retail pharmacy.
2.2. BoxeBehnken statistical design
One of the widely used response surface designs, a
BoxeBehnken statistical design with 3 factors, 3 levels, and 15
runs with triplicate center points was employed for the
formulation of floating gastroretentive tablets of ofloxacin.
Formulation design, optimization and other investigations
were done using Statgraphics Centurion XV software from
Stat-Point Technologies, USA, version 15.2.06. The indepen-
dent variables or the factors were the amount of HPMC K100M(X1), crosspovidone (X2) and NaHCO3 (X3). Levels of these fac-
tors were set in the formulation design on the basis of the
results of preliminary study and are coded as 1, 0, and þ1
(Table 1). The responses selected were the cumulative per-
centage drug release at 2 h (Y1), 8 h (Y2) and 12 h (Y3), floating
lag time (Y4) and the total floating time (Y5). Formulation
optimization was done by setting targets for these response
variables.2.3. Preparation of floating gastroretentive tablets
Tablets were prepared by conventional wet granulation
method using HPMC K100M as a release retardant, cross-
povidone as a swelling agents and NaHCO3 as gas generating
agent. Citric acid was also incorporated in the formulation to
provide sufficiently acidic medium for NaHCO3 to react and
maintain buoyancy. The compositions of designed 15 formu-
lations are listed in Table 2. All ingredients (except gas
generating agents and magnesium stearate) were passed
through sieve no. 60 and mixed in a polybag for 10 min and
granulated using PVP K30 (in isopropyl alcohol). The wet mass
was passed through sieve number 14 and dried in hot air oven
at 50 C for 1.5 h. Dried granules were mixed with remaining
ingredients and compressed using 16-station rotary tablet
press (Rimek Minipress-I, India) using 13 mm flat punch in
order to obtain controlled release floating gastroretentive
tablets containing 400 mg of ofloxacin.2.4. In vitro analysis
2.4.1. In vitro drug release study
Drug release from the tablets was studied using USP dissolu-
tion apparatus (Electrolab TDT-081, India), type I (basket
method). A tablet was placed inside a basket and immersed in
a dissolution vessel (n ¼ 6) containing 900 ml of 0.1 N HCl (pH
1.2), used as dissolution media at 37  0.5 C and stirred at a
speed of 100 rpm. The amount of drug released after 0.5, 1, 2, 3,
4, 6, 8, 10, 12, 14 and 16 h was determined using UVevisible
spectrophotometer (Shimadzu Corporation, 1601, Japan) at
294 nm. Release profiles of the designed formulations were
compared with that of the marketed formulation, “Zanocin
OD”. Similarity and difference factors were calculated using
appropriate formulas.
2.4.2. In vitro buoyancy study
The floating property of the tablets was visually determined in
triplicate. The floating lag time and the total floating time
were determined in the USP dissolution apparatus containing
0.1 NHCl (pH 1.2, maintained at 37 0.5 C). The time required
Table 2 e The composition of 15 formulations as per BoxeBehnken design.
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15
Ofloxacin 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
HPMC K100M 40 70 100 70 100 100 70 100 70 40 40 70 70 40 70
Crosspovidone 60 105 105 150 105 150 105 60 150 105 105 60 105 150 60
NaHCO3 75 75 60 60 90 75 75 75 90 60 90 90 75 75 60
Citric acid 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30
PVP K-30 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
Mag. Stearate 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15
Lactose 150 75 60 45 30 0 75 90 15 120 90 105 75 60 135
Total 810 810 810 810 810 810 810 810 810 810 810 810 810 810 810
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considered as floating lag time. The duration of time the
dosage form remained constantly on the surface of medium
was considered as the total floating time.
2.4.3. Drug release kinetics
In vitro release data were subjected to model fitting analysis to
know the order of drug release by treating the data according
to zero order, first order and Higuchi’s release kinetic equa-
tions. Since these kinetic models are generally unable to
explain the drug release mechanism from polymeric matrices
that undergo swelling and/or erosion during dissolution pro-
cess, the release data were further fitted into RitgerePeppas
empirical equation [7,13,14]. According to this equation,
Mt
MN
¼ Ktn
Here, Mt/MN is the fractional drug release at time t; K is the
release rate constant and n is the diffusional exponent indic-
ative of the release mechanism.
2.4.4. Compatibility of ofloxacin with excipients
To investigate the chemical interaction, Fourier Transformed
Infra Red (FTIR) analysis of admixture of ofloxacin and the
excipients used in the formulation were carried out over the
range of 400e4000 cm1 using FTIR spectrometer (Shimadzu,
IR Prestige 21, se Japan). The spectra produced by the pure
drug alone and in combination with excipients were
compared to confirm the interaction.2.5. In vivo evaluation
Inorder toascertain thepharmacokineticpropertyandexpected
clinical efficacy, in vivo evaluation of the optimized formulation
containing 400 mg ofloxacin was carried out. Open label, ran-
domized, two treatments, two periods, two sequences, single
dose, twoways crossover comparative bioavailability studywas
conductedusing healthy human subjects. Prior ethical approval
was taken from the Institutional Review Committee (IRC) of
Kathmandu University School of Medical Sciences/Dhulikhel
Hospital (IRC KUSMS), for carrying out this study (Protocol
approval number: 34/11). Pharmacokinetic data of optimized
formulation was compared with in vivo data of marketed
extendedreleaseproductofofloxacin400mg(ZanocinOD,Batch
no. 1760135).
Twelve healthy, non-smoking, adult Nepalese male volun-
teers were enrolled in the study.Written informed consent wasobtained from each subject after adequate explanation of the
objectives, methods and potential hazards of the study. All
volunteers gave medical screening examination before dosing
to establish their fitness to participate in the study. Enrolled
volunteers were randomly divided into two groups. One group
administered optimized formulation and another group
administered marketed formulation, “Zanocin OD” on the first
study day under fasting condition. After a washout period of 7
days, on the second study day, volunteers exchanged formu-
lations. In both study days, 5 ml of pre-dose blood sample was
collected 15min before drug administration. Later blood sample
was collected at 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16 and 24 h of drug
administration. Blood samples were collected in vacutainer
tubes without anticoagulant. It was allowed to clot at room
temperature for 20 min followed by centrifuging for 15 min at
5000 rpm. Serum was transferred into a separate serum
container and was promptly frozen at 40 C until assay.2.6. Drug analysis
2.6.1. Sample preparation
To 180 ml of thawed human serum sample, 20 ml of ciproflox-
acin (internal standard) was added and vortex mixed for 30 s.
600 ml of methanol was added to the tube. After mixing for
another 1 min the tube was centrifuged at 5000 rpm for 5 min
using a cooling centrifuge (Remi, India). 20 ml of filtered su-
pernatant was injected into the HPLC column for analysis.
2.6.2. Chromatographic conditions
Serum samples were analyzed for ofloxacin with a validated
bioanalytical method using HPLC (Shimadzu, Japan)
comprising of a pump (LC-20AD), autosampler (SIL-20AD),
photo-diode array detector (SPD-M20A) and a column oven
(CTO-10 ASVP). The data collection and integration was
accomplished using LC solutions software.
Separation was performed on a reverse phase CAPCELL
PAK C18, MG type column (250 mm length, 4.6 mm internal
diameter, 5 mm particle size) from Shiseido Fine Chemicals.
Mobile phase consisting of acetonitrile and 0.0625% triethyl-
amine in water (12.5: 87.5, pH adjusted to 2.5 with ortho-
phosphoric acid) was delivered at a flow rate of 1.5 ml/min.
The system was operated at wavelength of 294 nm and tem-
perature of column oven was set at 40 C.
The peaks of ofloxacin and ciprofloxacin were resolved
with good symmetry. The retention time for ofloxacin and
ciprofloxacinwas 8.2 0.8 and 9.3 0.76min respectively. The
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was validated as per ICH guidelines.
The serum drug concentrationetime data was subjected to
non-compartmental analysis using a pharmacokinetic soft-
ware, WinNonlin, standard edition, version 5.2.1 (Pharsight
Corporation, USA), to obtain various pharmacokinetic pa-
rameters. Relative bioavailability was determined as the ratio
of AUC0eN of optimized formulation to the AUC0eN of mar-
keted product.3. Results and discussion
3.1. Compatibility of ofloxacin with excipients
FTIR study revealed absence of potential chemical interaction
between the drug and excipients. The infrared spectrum of
ofloxacin alone showed characteristic peaks at 3427, 3043,
2968, 2785, 1716, 1620, 1550, 1458, 1056 cm1 [15]. All of these
typical peaks of ofloxacin remained unaffected in the spec-
trum of ofloxacin in combination with HPMC K100M and also
in presence of other excipients used in the formulation.
3.2. In vitro buoyancy
Most of the formulations were found to have good buoyancy
properties (Table 3). They floated immediately upon immer-
sion in to the media and remained floated for 16 h. NaHCO3
and citric acid were employed as gas forming agents
dispersed in the matrix and this formulation was found to be
appropriate for achieving desired buoyancy characteristics.
Addition of NaHCO3 was found essential to ensure rapid
floating. Furthermore, since the pH of the stomach is
elevated under fed condition (w3.5), citric acid was also
incorporated in the formulation to provide sufficiently acidic
medium for NaHCO3 to react. This will allow the system to
float independent of the pH of themedium. Upon immersion,
NaHCO3 starts reaction immediately with the acidicTable 3 e Observed responses in designed fifteen formulation
Formulations
Y1 (%) Y2 (%)
F1 50.62  7.20 81.09  7.81
F2 34.89  2.07 70.79  5.49
F 3 34.29  7.38 70.12  6.33
F 4 39.93  1.14 77.75  3.97
F 5 31.26  4.03 65.11  5.43
F 6 29.91  3.97 55.08  4.46
F 7 33.14  3.64 69.95  5.27
F 8 39.51  3.76 74.35  6.62
F 9 34.71  2.48 69.11  2.63
F10 61.64  3.51 96.70  4.14
F 11 48.89  4.17 69.28  4.96
F 12 28.84  4.13 53.98  4.59
F 13 37.16  6.66 75.10  4.38
F 14 41.64  2.77 75.15  6.59
F 15 31.28  4.62 70.48  1.92
a Data is expressed as mean  standard deviation.dissolution media and added citric acid. This reaction gen-
erates sufficient amount of CO2 which get entrapped and
protected within the gel layer formed by hydration of HPMC
K100M. This leads to decreased density of the tablet (reported
as 1.004e1.010 g/cm3), as a result of which the tablet becomes
buoyant [2,3,5,11,16e18]. Buoyancy property is further facil-
itated by relatively good acid solubility of ofloxacin which
causes faster penetration of dissolution media into the ma-
trix. This in turn causes quicker initiation of reaction
resulting in faster generation of CO2 making the tablets more
buoyant.
It hasbeenreported in several literatures that theamountof
NaHCO3 is directly related to the floating lag time [3,11,19e21].
As the amount of NaHCO3 increases, floating lag time de-
creases due to the generation of larger amount of efferves-
cence. However in this study, quantity of HPMC K100M was
found to have more prominent effect on floating characteris-
tics instead. Formulation containing higher amount of HPMC
K100M had better buoyancy property. Decreasing its amount
decreased floating duration and increased floating lag time
[20,22]. This effect is more noticeable in formulations con-
taining lesser amount of NaHCO3. When floating characteris-
tics of the fifteen formulations were compared, a longer
floating lag time and a shorter duration of floating were
observed in formulations F1, F10, F11 and F14 containing least
(40mgper tablet) amount ofHPMCK100M (Table 3). Thematrix
formedwith lower concentration of this polymer seems not to
be capable enough tohold thebubbles andfloat. Also therewas
quicker loss of tablet shape integrity in these formulations
which have further worsened their buoyancy property.
3.3. In vitro drug release
In vitro drug release and buoyancy study revealed that values
of responses for these 15 formulations varied markedly indi-
cating strong relationship between responses and the factors
(Table 3). The range of response Y1 was from 28.84% in F12 to
61.64% in F10. Response Y2 ranged from 53.98% in F12 to as.
Responsesa
Y3 (%) Y4 (s) Y5 (h)
96.00  1.89 1.00  00 1.00  00
85.61  4.71 25.00  5 16.00  00
80.97  2.04 1.00  00 16.00  00
92.34  1.53 1.00  00 16.00  00
83.37  5.79 1.00  00 16.00  00
68.99  5.47 1.00  00 16.00  00
84.57  4.87 1.00  00 16.00  00
79.57  5.34 54.00  7 16.00  00
81.44  3.27 1.00  00 16.00  00
100.00  00 95.00  5 1.00  0.15
82.97  6.28 156.00  10 0.50  0.10
69.61  4.95 1.00  00 7.00  0.27
90.63  0.47 1.00  00 16.00  00
98.36  1.88 22.00  15 4.00  0.23
88.31  0.87 78.00  12 4.00  0.25
Table 4 e Multiple response optimization.
Response (Range observed in
F1 e F15)
Target
value
% Cumulative
release at
at the end of,
Low High
(i) 2 h 29.91  3.97 61.64  3.51 37.08
(ii) 8 h 53.98  4.59 96.70  4.14 77.99
(iii) 12 h 68.99  5.47 100.00  00 92.03
Floating lag time (s) 1.00  00 156.00  10 Minimize
Total floating
duration (h)
0.50  0.10 16.00  00 Maximize
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in the range of 68.99 in F6 to 100% in F10.
Majority of the formulations extended the drug release for
16 h. Drug release from the hydrophillicmatrix tablet is known
to be a complex interaction between diffusion, swelling, and
erosion mechanisms. These processes are controlled by the
hydration of HPMC,which forms the gel barrier throughwhich
the drug diffuses [23]. Higher polymer concentration increase
the diffusion path length for the drug due to forming greater
amount of gel which retard drug release from the formulation.
The growth of erosion front, diffusion front, and swelling front
decrease with the increase in polymer proportion because of
the formation of a stronger gel layer, which make the entry of
medium into the matrix difficult [24e27].
In the present formulation design, amount of HPMC K100M
varied from 40 to 100 mg per tablet (5e12% of total tablet
weight). Formulations F1, F10, F11 and F14, containing low
concentration of HPMC K100M, gave high release rate of
50.62%, 61.64%, 48.89% and 41.64% respectively at the end of
2 h. Also these formulations completed drug release within a
short time. When quantity of HPMC K100M was increased to
100 mg per tablet in formulations F3, F5, F6 and F8, release at
the end of 2 h decreased down to 34.29%, 31.26%, 29.91% and
39.51% respectively. These formulations successfully
extended drug release for sufficiently longer duration. At the
end of 16 h drug release from formulations F3, F5, F6 and F8
were found to be 93.08, 93.02, 80.01 and 90.54% respectively.
It has been observed that high release occurred in all
designed formulations at the end of 2 h.Marketed product also
gave a high release rate of 37.08%at the end of 2 h. Such type of
release could be due to the reason that the gel layer, which
controls drug release needs sometime to become effective. Till
the gel barrier is being formed, high rate of erosion occurs
resulting in high initial drug release [23,27,28]. After some time
release rate slows down as polymer hydration occurs.
In vitro release data were fitted in to different release ki-
netic models and it was observed that regression coefficient
was highest for the Higuchimodel (except for F10 & F11). The n
values for all formulations, except F1, F10, F11 and F14, were
found to be lying within the range of 0.45e0.89, indicating
anomalous or non-Fickian type of diffusion to be the pre-
determining mechanism of drug release.
Mathematical relationships for the measured responses
and the independent variables or factors were generated with
the help of software Statgraphics Centurion XV and are shown
in Equations (1)e(5). These equations represent the quantita-
tive effect of variables (X1, X2, X3) and their interactions on the
response. Coefficient with more than one factor term and
thosewith higher order terms represent interaction terms and
quadratic relationship respectively. A positive sign represents
synergistic effect, while a negative sign indicates antagonistic
effect or an inverse relationship between the factors and
response [29]. Correlation coefficient (r2) for the equations
indicates the percentage variability in model fitting for that
particular variable. The adjusted r2 value is more suitable for
comparing models with different number of independent
variables which can be obtained by including only statistically
significant (P < 0.05) coefficients in the equation. In this study
final equation was considered with maximum adjusted r2
value. The adjusted r2 value for responses Y1, Y2, Y3 and Y5were found to be 79.97, 80.51, 84.73 and 88.27% respectively,
which indicate good fit. When ANOVA was performed at 95%
confidence interval to estimate the significance of the model,
factors X1 (HPMC) and X3 (NaHCO3) were identified as critical
influencing parameters for selected responses Y1, Y2 and Y3.
Another response, Y5, i.e. the total floating time was found to
be affected significantly by the amount of HPMC (X1) and CP
(X2) whilst no significant effect of formulation variables was
observed on Y4, i.e. floating lag time.
Y1 ¼ 111:946 1:518X1  0:195X3 þ 0:009$X21 (1)
r2 ¼ 86:41%; r2ðadjustedÞ ¼ 79:97%
Y2 ¼ 169:080 1:456X1 þ 0:587X2  1:351X3 þ 0:004X21
 0002X1X2 þ 0:012X1X3  0:002X22 (2)
r2 ¼ 87:43%; r2ðadjustedÞ ¼ 80:51%
Y3 ¼ 173:766 1:130X1 þ 0:908X2  1:775X3 þ 0:005X21
 0008X1X2 þ 0:014X1X3  0:003X22 þ 0:004X2X3 (3)
r2 ¼ 86:39%; r2ðadjustedÞ ¼ 84:73%
Y4 ¼ 932:302 5:271X1  19:122X3 þ 0:031X21 þ 0:127X23 (4)
r2 ¼ 37:53%; r2ðadjustedÞ ¼ 20:50%
Y5 ¼ 121:083þ 0:949X1 þ 0:294X2 þ 2:042X3  0:005X21
 0:002X22  0:014X3 (5)
r2 ¼ 92:46%; r2ðadjustedÞ ¼ 88:27%
3.4. Formulation optimization and evaluation
For formulation optimization, target values for the responses
(Y1 e Y5) were set on the basis of in vitro drug release and
buoyancy study of marketed product, “Zanocin OD” (Table 4).
Composition of the optimized formulation given by the soft-
ware using this technique termed as “multiple response
optimization” is shown in Table 5. This combination maxi-
mized the desirability over the indicated region to 0.93 (Fig. 1).
Optimized formulation had good physicochemical prop-
erties and was found to fulfill the requirement of an optimum
Table 5 e Composition of optimized formulation.
Composition Amount per
tablet (mg)
% per
tablet weight
Ofloxacin 400.00 49.38
HPMC K100M 66.02 8.15
Crosspovidone 107.88 13.32
NaHCO3 67.17 8.29
Citric acid 30.00 3.70
PVP K30 40.00 4.94
Magnesium Stearate 15.00 1.85
Lactose 83.93 10.36
Total 810.00 100.00
Crosspovidone = 105.0
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Fig. 1 e Counter plot showing effect of HPMC K100M and
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drug release at the end of 2, 8 and 12 h. The predicted release
profile, given by the software was found to be quite close to
the profile obtained experimentally which indicates the val-
idity of the developed model (Table 6). Floating lag time of
optimized formulation was 2.56 s and it remained floated for
more than 16 h in vitro. Thus, besides controlling drug release
for an extended duration, the formulation seemed to have an
excellent floating potential which is prerequisite for prolong
residence of the dosage form in the stomach.
The respective release profiles of the marketed and opti-
mized formulation superimposed over each other which in-
dicates analogy of their release performances (Fig. 2).
Comparison of release profile of optimized and marketed
formulations gave similarity factor ( f2) of 79.22 and differenceTable 6 e Response variables and release kinetics of
marketed product and optimized formulation (observed
and predicted).
Formulation Response variables Higuchi
model
n
Y1
(%)
Y2
(%)
Y3
(%)
Y4
(s)
Y5
(h)
KH r2
Marketed 37.08 77.99 92.02 2.00 >16 27.10 0.98 0.55
Optimized
(predicted)
37.08 77.06 93.82 2.72 17.36 23.45 0.99 0.52
Optimized
(observed)
39.77 76.09 89.89 2.56 >16 26.01 0.99 0.52factor ( f1) of 3.84. Table 6 shows the comparison of the
response variables and other release parameters of these
formulations. Percentage cumulative drug release at 2 (Y1), 8
(Y2) and 12 h (Y3) from optimized formulationwere found to be
quite close to that of marketed product. Buoyancy parameters
like floating lag time (Y4) and total floating duration (Y5) of
these formulations were also lying in close proximity to each
other (Table 6). Drug release from both optimized and mar-
keted formulation followed Higuchi’s release kinetics and the
values of n were found to be 0.52 and 0.55 respectively sug-
gesting the release mechanism to be anomalous transport.3.5. Pharmacokinetic evaluation
The mean serum concentration versus time profiles of the
optimized and marketed formulations were similar and0
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Fig. 3 e Overlain mean serum ofloxacin
concentrationetime profiles after oral single dose
administration of optimized and marketed formulation in
12 healthy human volunteers.
Table 7 e Pharmacokinetic profiles of optimized and
marketed formulation.
Parameters Marketed
formulation
Optimized
formulation
P value
Cmax (mg/ml) 3.47  0.70 3.94  0.39 0.04
AUC0e24 (mg h/ml) 36.85  4.77 41.80  4.83 0.03
AUC0eN (mg h/ml) 43.33  8.82 47.94  6.41 0.06
tmax(h) 5.67  1.97 5.75  1.48 e
t ½(h) 7.36  2.57 7.20  1.52 e
Kel 0.10  0.32 0.10  0.02 e
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of these formulations are presented in Table 7.
90% confidence interval of the ratio of mean AUC0e24,
AUC0eN and Cmax of the optimized to marketed formulation
were found to be in the range of 94.27%e103.85%; 99.97%e
110.11% and 98.59e111.86% respectively. These values are
within the bioequivalence accepted range of 80%e125%
[30,31]. Thus, the two formulations can be regarded bio-
equivalent and hence interchangeable.4. Conclusions
Controlled release floating gastroretentive tablet dosage form
of ofloxacin was successfully developed using BoxeBehnken
statistical design. Serum drug level monitoring in human
subjects for 24 h showed extended drug release for sufficiently
longer duration making its once daily administration suffi-
cient. Serum ofloxacin concentration was maintained well
above the reported minimum inhibitory concentrations for
most of the pathogens for longer duration. The optimized
formulation, when compared to the conventional immediate
release preparation, seems to be promising for improving
bioavailability of ofloxacin for enhancing its therapeutic effi-
cacy along with improving patient convenience due to less
frequent dosing requirement.
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